Literature DB >> 21246162

Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?

S Kang1, B-C Ahn, C M Hong, B-I Song, H J Lee, S Y Jeong, S-W Lee, J Lee, S J Lee.   

Abstract

UNLABELLED: The AIM of this study was to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) of primary cutaneous malignant melanoma (CMM) lesions by (18)F-FDG positron emission tomography/computerized tomography (PET/CT) in terms of recurrence. PATIENTS,
METHODS: 37 CMM patients (17 men, mean age: 61.7 ± 13.6 years) that underwent PET/CT at presentation were enrolled in this study. Recurrence was determined by histological confirmation or by radiological and clinical follow-up for at least 8 months after curative surgery. Clinical variables such as age, sex, clinical stage, and primary lesion location, thickness, and ulceration, and SUVmax values were analyzed with respect to their usefulness for predicting recurrence.
RESULTS: SUVmax was found to be significantly higher in patients with ulceration of primary lesion of CMM (p = 0.004) and in patients with a stage ≥ III (p < 0.000). Patients that experience recurrence had a significantly higher mean SUVmax value (4.9 ± 2.9) than patients who did not (2.1 ± 1.5, p = 0.024). ROC analysis showed that a SUVmax cut-off value 2.2 had high sensitivity (88.9%) and specificity (67.9%) for predicting recurrence. Kaplan-Meier analysis identified ulceration of primary lesion (p = 0.034), stage ≥ III (p = 0.019) and SUVmax ≥ 2.2 (p = 0.002) as predictors of recurrence. However, Cox proportional-hazards analysis showed that only SUVmax (p = 0.025, relative risk 11.063) significantly predicted recurrence.
CONCLUSION: Preoperative SUVmax of primary lesion was found to be the most potent predictor of recurrence in CMM patient. Patients with high SUV max of primary lesion should be followed meticulously for recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21246162     DOI: 10.3413/Nukmed-0356-10-09

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  7 in total

1.  Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Authors:  Romain-David Seban; John S Nemer; Aurélien Marabelle; Randy Yeh; Eric Deutsch; Samy Ammari; Antoine Moya-Plana; Fatima-Zohra Mokrane; Robyn D Gartrell; Grace Finkel; Luke Barker; Amélie E Bigorgne; Lawrence H Schwartz; Yvonne Saenger; Caroline Robert; Laurent Dercle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-25       Impact factor: 9.236

Review 2.  Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus.

Authors:  Begoña Campos-Balea; Ovidio Fernández-Calvo; Roberto García-Figueiras; Carlos Neira; Carmen Peña-Penabad; Carmela Rodríguez-López; Rocío Vílchez-Simo; María Quindós-Varela
Journal:  Clin Transl Oncol       Date:  2022-03-28       Impact factor: 3.340

Review 3.  Precision Medicine and PET/Computed Tomography in Melanoma.

Authors:  Esther Mena; Yasemin Sanli; Charles Marcus; Rathan M Subramaniam
Journal:  PET Clin       Date:  2017-07-14

4.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

5.  Elevated tumor-to-liver uptake ratio (TLR) from 18F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection.

Authors:  Jun Huang; Liang Huang; Jiaming Zhou; Yinghua Duan; Zhanwen Zhang; Xiaoyan Wang; Pinzhu Huang; Shuyun Tan; Ping Hu; Jianping Wang; Meijin Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-15       Impact factor: 9.236

Review 6.  Imaging findings of malignant skin tumors: radiological-pathological correlation.

Authors:  Masaya Kawaguchi; Hiroki Kato; Yoshifumi Noda; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Fuminori Hyodo; Masayuki Matsuo
Journal:  Insights Imaging       Date:  2022-03-22

7.  The Use of 18F-FDG PET/CT Metabolic Parameters in Predicting Overall Survival in Patients Undergoing Restaging for Malignant Melanoma.

Authors:  Khanyisile N Hlongwa; Kgomotso M G Mokoala; Zvifadzo Matsena-Zingoni; Mariza Vorster; Mike M Sathekge
Journal:  Diagnostics (Basel)       Date:  2022-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.